Patient info Search Menu

Dermol Wash Cutaneous Emulsion – Summary of Product Characteristics (SmPC) for healthcare professionals

Updated:
Key facts
Status:
Pharmacy medicine (P)
Medicine strength:
25 mg/gram + 25 mg/gram + 1 mg/gram + 1 mg/gram

Summary of Product Characteristics (SmPC) - Dermol Wash cutaneous emulsion

1 NAME OF THE MEDICINAL PRODUCT

Dermol Wash Cutaneous Emulsion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Liquid paraffin 2.5% w/w

Isopropyl myristate 2.5% w/w

Benzalkonium chloride 0.1% w/w

Chlorhexidine dihydrochloride 0.1% w/w

Excipients with known effect:

Cetostearyl alcohol

For the full list of excipients, see Section 6.1

3 PHARMACEUTICAL FORM

Cutaneous emulsion

White, non-greasy cutaneous emulsion.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

An antimicrobial emollient for the management of dry and pruritic skin conditions, especially eczema and dermatitis. Dermol Wash Cutaneous Emulsion is suitable for direct application and for use as a soap substitute.

4.2 Posology and method of administration

For adults, children and the elderly. For cutaneous use only.

For use as a soap substitute

Use as a cleanser at the sink or to wash with in the bath or shower, instead of ordinary soap or shower gel. Pat the skin dry using a soft towel (avoid rubbing as this can irritate the skin).

The product may also be used in a similar way for frequent hand washing.

For application to the skin (eg after washing)

Apply to the affected areas as required.

4.3 Contraindications

Do not use in cases of known sensitivity (especially generalised allergic reaction) to any of the ingredients (see sections 4.4 and 4.8).

4.4 Special warnings and precautions for use

Avoid contact with the eyes.

Take care to avoid slipping in the shower or bath, when using as a soap substitute.

Local skin reactions (e.g. contact dermatitis) to any of the ingredients are rare but possible in sensitive people.

There are literature reports of chlorhexidine compounds inducing hypersensitivity, including anaphylactic shock. The prevalence of this is not known, but is likely to be very rare. Dermol Wash Cutaneous Emulsion should not be administered to anyone with a possible history of allergic reaction to a chlorhexidine compound (see sections 4.3 and 4.8).

Dermol Wash Cutaneous Emulsion contains cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).

Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Use during pregnancy and lactation is not expected to be associated with harmful effects to the mother as cutaneous absorption of benzalkonium chloride is minimal. When breast-feeding, if use on the nipples is necessary, apply sparingly and after feeds. Gently wipe away any remaining product before feeding your baby.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Although the product has been specially formulated for use on dry or problem skin, in the unlikely event of a reaction discontinue treatment.

Local skin reactions

These reactions are very rare (<1/10,000, based on spontaneous reporting) and may be irritant or allergic in nature. Reactions have been observed occasionally when used excessively as a leave-on application in areas of folded skin such as the anogenital area.

Serious generalised allergic reactions

Very rarely, hypersensitivity including anaphylactic reaction (see sections 4.3 and 4.4) is possible (based on literature for chlorhexidine-containing products).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Not applicable.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC code: D02 AX, emollients and protectives.

Bacteria (especially Staphylococcus aureus) are implicated in the pathogenesis of inflammatory dry skin conditions such as atopic eczema and dermatitis.

Dermol Wash contains 5% of emollient oils in a non-greasy aqueous system which also contains the well-known and effective antiseptics benzalkonium chloride and chlorhexidine dihydrochloride. Its antimicrobial properties assist in overcoming infection, whether from Staph aureus, the pathogen which often complicates eczema and associated pruritus, or secondary infection caused by scratching.

Massaged into the skin, the emollients, liquid paraffin and isopropyl myristate, permit rehydration of dry skin by forming an occlusive barrier within the skin surface, thus reducing drying from evaporation of water that diffuses from the underlying layers.

5.2 Pharmacokinetic properties

The active ingredients are presented in an aqueous emulsion system and so are readily absorbed into the stratum corneum when the product is gently massaged over the areas of dry skin. The antiseptic ingredients are in intimate contact with the skin, and as they are in solution, their availability is optimal.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Macrogol cetostearyl ether (cetomacrogol 1000) Cetostearyl alcohol

Phenoxyethanol

Sodium hydroxide

Purified water

6.2 Incompatibilities

None known.

6.3 Shelf life

18 months in unopened container

6.4 Special precautions for storage

Do not store above 25°C.

Replace cap after use.

6.5 Nature and contents of container

High density polyethylene bottle (50, 200 or 500 ml) with either a white polypropylene metering pump or a white polypropylene dispensing stopper/screw cap.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Diomed Developments Limited

T/A Dermal Laboratories

Tatmore Place

Gosmore

Hitchin

Hertfordshire, SG4 7QR

UK

8 MARKETING AUTHORISATION NUMBER(S)

PL 00173/0407

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

17/10/2024

10 DATE OF REVISION OF THE TEXT

16/07/2026

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00173/0407

Last revision stated in the text: 16 July 2026 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Dermol Wash cutaneous emulsion

What these facts mean

Prescription needed?? No, but it is sold only in pharmacies (P)
Active substances? Liquid paraffin, Isopropyl myristate, Benzalkonium chloride, Chlorhexidine hydrochloride
Strength? 25 mg/gram + 25 mg/gram + 1 mg/gram + 1 mg/gram
Pharmaceutical form? Cutaneous emulsion
White, non-greasy cutaneous emulsion.
How is it taken? Cutaneous
Excipients? Macrogol cetostearyl ether (cetomacrogol 1000) Cetostearyl alcohol, Phenoxyethanol, Sodium hydroxide, Purified water
Pack sizes 200 ml
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 18 months in unopened container
Storage Do not store above 25°C.
Replace cap after use.
Marketing authorisation? PL 00173/0407 (first authorised 17 October 2024)
Marketing authorisation holder? Diomed Developments Limited
Codes? GTIN 5016379157004 · BNF 13020101

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.0.0 of 2 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.